TF and COVID-19: Studies have shown that EV-TF activity is significantly increased in hospitalized patients with COVID-19, and TF-positive EVs are released into the circulation, which may lead to thrombosis, increasing disease severity and mortality (Guervilly et al., 2021; Rosell et al., 2021).